Skye Bioscience Inc (SKYE) has a current Price-to-Book (P/B) ratio of 0.83. Compared to its 3-year average P/B ratio of -1.71, the current P/B ratio is approximately -148.57% higher. Relative to its 5-year average P/B ratio of 0.04, the current P/B ratio is about 2119.03% higher. Skye Bioscience Inc (SKYE) has a Forward Free Cash Flow (FCF) yield of approximately -147.50%. Compared to its 3-year average FCF yield of -42.80%, the current FCF yield is approximately 244.60% lower. Relative to its 5-year average FCF yield of -40.56%, the current FCF yield is about 263.62% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SKYE competitors is 3.48, providing a benchmark for relative valuation. Skye Bioscience Inc Corp (SKYE.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SKYE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SKYE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SKYE currently overvalued or undervalued?

What is Skye Bioscience Inc (SKYE) fair value?

SKYE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Skye Bioscience Inc (SKYE) is between to according to relative valuation method.

How does SKYE's valuation metrics compare to the industry average?

The average P/S ratio for SKYE's competitors is 3.48, providing a benchmark for relative valuation. Skye Bioscience Inc Corp (SKYE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Skye Bioscience Inc (SKYE) as of Mar 05 2026?

As of Mar 05 2026, Skye Bioscience Inc (SKYE) has a P/B ratio of 0.83. This indicates that the market values SKYE at 0.83 times its book value.

What is the current FCF Yield for Skye Bioscience Inc (SKYE) as of Mar 05 2026?

As of Mar 05 2026, Skye Bioscience Inc (SKYE) has a FCF Yield of -147.50%. This means that for every dollar of Skye Bioscience Inc's market capitalization, the company generates -147.50 cents in free cash flow.

What is the current Forward P/E ratio for Skye Bioscience Inc (SKYE) as of Mar 05 2026?

As of Mar 05 2026, Skye Bioscience Inc (SKYE) has a Forward P/E ratio of -0.74. This means the market is willing to pay $-0.74 for every dollar of Skye Bioscience Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Skye Bioscience Inc (SKYE) as of Mar 05 2026?

As of Mar 05 2026, Skye Bioscience Inc (SKYE) has a Forward P/S ratio of 0.00. This means the market is valuing SKYE at $0.00 for every dollar of expected revenue over the next 12 months.

SKYE Valuation